|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123261 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-23 10:42:11 |
|
注册时间: Date of Registration: |
2026-04-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
慢阻肺急性加重并发静脉血栓栓塞症中西医协同风险预测模型的构建研究 |
|
Public title: |
Construction Study of an Integrated Chinese and Western Medicine Risk Prediction Model for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated by Venous Thromboembolism |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
慢阻肺急性加重并发静脉血栓栓塞症中西医协同风险预测模型的构建研究 |
|
Scientific title: |
Construction Study of an Integrated Chinese and Western Medicine Risk Prediction Model for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated by Venous Thromboembolism |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴蔚 |
研究负责人: |
吴蔚 |
|
Applicant: |
Wu Wei |
Study leader: |
Wu Wei |
|
申请注册联系人电话: Applicant telephone: |
+86 10 84739044 |
研究负责人电话:
Study leader's |
+86 10 84739044 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
drwv@163.com |
研究负责人电子邮件: Study leader's E-mail: |
13651285699@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区望京中环南路6号 |
研究负责人通讯地址: |
北京市朝阳区望京中环南路6号 |
|
Applicant address: |
No. 6, South Central Ring Road, Wangjing, Chaoyang District, Beijing |
Study leader's address: |
No. 6, South Central Ring Road, Wangjing, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国中医科学院望京医院 |
||
|
Applicant's institution: |
Wangjing Hospital, China Academy of Chinese Medical Sciences |
||
|
研究负责人所在单位: |
中国中医科学院望京医院 |
||
|
Affiliation of the Leader: |
Wangjing hospital of Chinese academy of trditional Chinese medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
WJEC-KT-2026-009-P001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国中医科学院望京医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethic Committee of Wang Jing Hospital of CACMS |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-06 00:00:00 | ||
|
伦理委员会联系人: |
王浩 |
||
|
Contact Name of the ethic committee: |
Peter Wang |
||
|
伦理委员会联系地址: |
北京市朝阳区望京中环南路6号 |
||
|
Contact Address of the ethic committee: |
6 south zhonghuan road,wangjing, chaoyang district,Beijing China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 84739681 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
peterxfx@126.com |
|
研究实施负责(组长)单位: |
中国中医科学院望京医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wangjing hospital of Chinese academy of trditional Chinese medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区望京中环南路6号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 6, South Central Ring Road, Wangjing, Chaoyang District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国中医科学院望京医院自主选题专项课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self selected Special Project of Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
慢性阻塞性肺疾病急性加重 |
||||||||||||||||||||||
|
Target disease: |
Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
应用人工智能技术整合现代医学检测指标及中医证素等大规模、多维度数据,挖掘AECOPD并发VTE的危险因素,数智化驱动中西医协同风险预测模型的构建及验证,精准识别AECOPD并发VTE高危人群及干预时机,指导个体化防治方案的制定,增强临床决策的科学性,为开展“中西医协同-分层干预”奠定基础,提升重大慢病防治能力,降低病死率。 |
||||||||||||||||||||||
|
Objectives of Study: |
To apply artificial intelligence techniques to integrate large?scale, multi?dimensional data including modern medical detection indicators and traditional Chinese medicine syndromes, explore the risk factors of AECOPD complicated with VTE, and construct and validate a digitally intelligent?driven integrated traditional Chinese and Western medicine risk prediction model. This model aims to accurately identify high?risk populations and optimal intervention timing for AECOPD?associated VTE, guide the formulation of individualized prevention and treatment strategies, enhance the scientificity of clinical decision?making, lay a foundation for the implementation of an “integrated traditional Chinese and Western medicine?stratified intervention” model, improve the prevention and control capacity of major chronic diseases, and reduce mortality. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合AECOPD诊断标准; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Meet the diagnostic criteria for AECOPD; |
||||||||||||||||||||||
|
排除标准: |
1.入组前已明确诊断静脉血栓栓塞性疾病,正在抗凝治疗中的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with a confirmed diagnosis of venous thromboembolism before enrollment and who were receiving anticoagulant therapy; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2027-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label study |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NONE |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子数据采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Clinical Electronic Data Capture System (EDC System) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |